Hofseth BioCare ASA
Hofseth BioCare ASA produces and sells health nutritional products for humans and pets in Norway, the United Kingdom, France, Belgium, Italy, Germany, rest of Europe, Japan, Asia, and the United States. The company offers ProGo, a bioactive peptide for weight management and metabolic health; OmeGo, a salmon oil that provides a full spectrum of fatty acids and omegas; CalGo and NT-II, which are ca… Read more
Hofseth BioCare ASA (HOFBF) - Net Assets
Latest net assets as of December 2025: $-75.53 Million USD
Based on the latest financial reports, Hofseth BioCare ASA (HOFBF) has net assets worth $-75.53 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($394.27 Million) and total liabilities ($469.81 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-75.53 Million |
| % of Total Assets | -19.16% |
| Annual Growth Rate | N/A |
| 5-Year Change | -153.81% |
| 10-Year Change | -241.02% |
| Growth Volatility | 86.04 |
Hofseth BioCare ASA - Net Assets Trend (2010–2025)
This chart illustrates how Hofseth BioCare ASA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hofseth BioCare ASA (2010–2025)
The table below shows the annual net assets of Hofseth BioCare ASA from 2010 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-75.53 Million | -223.21% |
| 2024-12-31 | $61.30 Million | +49.01% |
| 2023-12-31 | $41.14 Million | -72.21% |
| 2022-12-31 | $148.03 Million | +5.45% |
| 2021-12-31 | $140.38 Million | -46.78% |
| 2020-12-31 | $263.76 Million | +124.00% |
| 2019-12-31 | $117.75 Million | +36.85% |
| 2018-12-31 | $86.04 Million | +132.03% |
| 2017-12-31 | $37.08 Million | -30.77% |
| 2016-12-31 | $53.56 Million | +64.58% |
| 2015-12-31 | $32.55 Million | -58.78% |
| 2014-12-31 | $78.95 Million | +27.33% |
| 2013-12-31 | $62.00 Million | +29.94% |
| 2012-12-31 | $47.72 Million | -60.41% |
| 2011-12-31 | $120.53 Million | +58.66% |
| 2010-12-31 | $75.97 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hofseth BioCare ASA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1013500000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Total Equity | $-74.84 Million | 100.00% |
Hofseth BioCare ASA Competitors by Market Cap
The table below lists competitors of Hofseth BioCare ASA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wetteri
HE:WETTERI
|
$14.89 Million |
|
Grande Hospitality Real Estate Investment Trust
BK:GAHREIT
|
$14.89 Million |
|
Kingsmen Resources Ltd
OTCQB:KNGRF
|
$14.90 Million |
|
Groupe Partouche SA
PA:PARP
|
$14.90 Million |
|
FAIR ISAAC
BE:FRI
|
$14.89 Million |
|
Telefield Inc
KQ:091440
|
$14.88 Million |
|
Tayih Lun An Co Ltd
TWO:8107
|
$14.88 Million |
|
Baumer S.A
SA:BALM3
|
$14.88 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hofseth BioCare ASA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 61,993,000 to -74,844,000, a change of -136,837,000 (-220.7%).
- Net loss of 134,881,000 reduced equity.
- Other factors decreased equity by 1,956,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-134.88 Million | -180.22% |
| Other Changes | $-1.96 Million | -2.61% |
| Total Change | $- | -220.73% |
Book Value vs Market Value Analysis
This analysis compares Hofseth BioCare ASA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | $2.67 | $0.10 | x |
| 2011-12-31 | $2.73 | $0.10 | x |
| 2012-12-31 | $0.82 | $0.10 | x |
| 2013-12-31 | $0.84 | $0.10 | x |
| 2014-12-31 | $0.86 | $0.10 | x |
| 2015-12-31 | $0.31 | $0.10 | x |
| 2016-12-31 | $0.37 | $0.10 | x |
| 2017-12-31 | $0.16 | $0.10 | x |
| 2018-12-31 | $0.33 | $0.10 | x |
| 2019-12-31 | $0.39 | $0.10 | x |
| 2020-12-31 | $0.79 | $0.10 | x |
| 2021-12-31 | $0.39 | $0.10 | x |
| 2022-12-31 | $0.40 | $0.10 | x |
| 2023-12-31 | $0.11 | $0.10 | x |
| 2024-12-31 | $0.15 | $0.10 | x |
| 2025-12-31 | $-0.19 | $0.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hofseth BioCare ASA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -52.62%
- • Asset Turnover: 0.65x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-113.35%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -12.36% | -5489.47% | 0.00x | 1.24x | $-16.98 Million |
| 2011 | -15.80% | -1609.13% | 0.01x | 1.31x | $-31.08 Million |
| 2012 | -152.90% | -283.91% | 0.17x | 3.22x | $-78.69 Million |
| 2013 | -83.26% | -82.84% | 0.31x | 3.27x | $-58.40 Million |
| 2014 | -84.08% | -338.50% | 0.09x | 2.74x | $-74.88 Million |
| 2015 | -301.84% | -181.72% | 0.29x | 5.82x | $-103.51 Million |
| 2016 | -271.94% | -729.81% | 0.13x | 2.94x | $-152.87 Million |
| 2017 | -43.64% | -13.91% | 0.64x | 4.88x | $-20.25 Million |
| 2018 | -97.75% | -139.56% | 0.32x | 2.17x | $-93.44 Million |
| 2019 | -75.33% | -131.62% | 0.23x | 2.47x | $-101.05 Million |
| 2020 | -38.60% | -147.42% | 0.15x | 1.74x | $-128.53 Million |
| 2021 | -89.65% | -144.34% | 0.21x | 2.95x | $-140.57 Million |
| 2022 | -92.38% | -114.06% | 0.29x | 2.76x | $-152.26 Million |
| 2023 | -255.06% | -54.74% | 0.50x | 9.33x | $-110.87 Million |
| 2024 | -199.06% | -47.94% | 0.75x | 5.51x | $-129.60 Million |
| 2025 | 0.00% | -52.62% | 0.65x | 0.00x | $-127.40 Million |
Industry Comparison
This section compares Hofseth BioCare ASA's net assets metrics with peer companies in the Packaged Foods industry.
Industry Context
- Industry: Packaged Foods
- Average net assets among peers: $5,681,533,529
- Average return on equity (ROE) among peers: 0.04%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hofseth BioCare ASA (HOFBF) | $-75.53 Million | -12.36% | N/A | $14.89 Million |
| Above Food Ingredients Inc. Common Stock (ABVE) | $30.90K | -3.31% | 7.66x | $18.76 Million |
| The a2 Milk Company Limited (ACOPF) | $7.27 Million | -30.19% | 0.14x | $3.91 Billion |
| Ayujoy Herbals Ltd (AJOY) | $22.20 Million | 29.29% | 0.00x | $95.71 |
| Alfa S.A.B. de C.V (ALFFF) | $53.35 Billion | 7.36% | 3.80x | $2.16 Billion |
| Amincor Inc (AMNCB) | $34.44 Million | -63.76% | 0.81x | $2.24K |
| Armanino Foods New (AMNF) | $21.40 Million | 30.30% | 0.33x | $72.33K |
| Amira Nature Foods Ltd (ANFIF) | $303.22 Million | 8.27% | 0.89x | $128.79 |
| AAK AB (publ.) (ARHUF) | $2.44 Billion | 12.85% | 2.63x | $5.07 Billion |
| Artisan Consumer Goods Inc (ARRT) | $-326.75K | 0.00% | 0.00x | $279.39K |
| ARYZTA AG (ARZTF) | $632.10 Million | 9.58% | 2.04x | $53.13 Million |